Preventive aspirin and other antiplatelet medication use among U.S. adults aged≥ 40 years: Data from the national health and nutrition examination survey, 2011–2012

Public Health Reports

Volumn 130, Issue 6, 2015, Pages 643-654

  Gu, Qiuping ^a   Dillon, Charles F ^a   Eberhardt, Mark S ^a   Wright, Jacqueline D ^b   Burt, Vicki L ^a  

^a NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; PRASUGREL; TICLOPIDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASIAN; BLACK PERSON; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE SURVEY; HEALTH INSURANCE; HEART INFARCTION; HISPANIC; HISTORY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; SECONDARY PREVENTION; SELF MEDICATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; AGE; DRUG UTILIZATION REVIEW; QUESTIONNAIRE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASPIRIN; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION REVIEW; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84945537309     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491513000614     Document Type: Article

References (40)

1. George MG, Tong X, Sonnenfeld N, Hong Y. Recommended use of aspirin and other antiplatelet medications among adults—National Ambulatory Medical Care Survey and National Hospital Ambula­tory Medical Care Survey, United States, 2005–2008. MMWR Morb Mortal Wkly Rep 2012;61(Suppl):11-8.
2. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Ath­erosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-73.
3. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76.
4. Park K, Bavry AA. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Cleve Clin J Med 2013;80:318-26.
5. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
6. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
7. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of ran­domized controlled trials [published erratum appears in JAMA 2006;295:2002]. JAMA 2006;295:306-13.
8. Bayer. Bayer safety coated aspirin: comprehensive prescribing information [cited 2014 Jul 25]. Available from: URL: http:// www.fda.gov/ohrms/dockets/ac/03/briefing/4012B1_03_Appd %201-Professional%20Labeling.pdf
9. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to com­prehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Associa­tion Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.
10. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, et al. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures. Circulation 2009;120:1296-336.
11. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.
12. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-701.
13. Preventive Services Task Force (US). Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recom­mendation statement. Ann Intern Med 2009;150:396-404.
14. Frieden TR, Berwick DM. The “Million Hearts” initiative—preventing heart attacks and strokes. N Engl J Med 2011;365:e27.
15. Sacco RL, Frieden TR, Blakeman DE, Jauch EC, Mohl S. What the Million Hearts initiative means for stroke: a presidential advisory from the American Heart Association/American Stroke Association. Stroke 2012;43:924-8.
16. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2:e353.
17. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30:74-7.
18. Brown DW, Shepard D, Giles WH, Greenlunk KJ, Croft JB. Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Ethn Dis 2005;15:620-6.
19. Soni A. Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Statistical Brief #179. 2007. Rockville (MD): Agency for Healthcare Research and Quality; 2007. Also available from: URL: http://meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179 .pdf[cited 2014 Jul 25].
20. National Center for Health Statistics (US). 2012 National Health Interview Survey, sample adult. 2013 [cited 2014 Jul 25]. Available from: URL: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Survey _Questionnaires/NHIS/2012/English/qadult.pdf
21. Mainous AG, Tanner RJ, Shorr RI, Limacher MC. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J Am Heart Assoc 2014;3:e000989.
22. Fiscella K, Winters PC, Mendoza M, et al. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease? J Gen Intern Med 2015;30:155-60.
23. National Center for Health Statistics (US). National Health and Nutrition Examination Survey: unweighted response rates for NHANES 2011–2012 by age and gender [cited 2014 Jul 25]. Available from: URL: http://www.cdc.gov/nchs/data/nhanes /response_rates_cps/rrt1112.pdf
24. National Center for Health Statistics (US). 2011–2012 National Health and Nutrition Examination Survey [cited 2014 Jul 25]. Available from: URL: http://www.cdc.gov/nchs/data/nhanes /nhanes_11_12/dsq.pdf
25. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Mas­saro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
26. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
27. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8.
28. SAS Institute, Inc. SAS®: Version 9.3 for Windows. Cary (NC): SAS Institute, Inc.; 2010.
29. RTI International. SUDAAN®: Release 11.0. Research Triangle Park (NC): RTI International; 2012.
30. National Center for Health Statistics (US). Analytic and reporting guidelines: the National Health and Nutrition Examination Survey (NHANES). 2005 [cited 2014 Jul 25]. Available from: URL: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic _guidelines_dec_2005.pdf
31. National Center for Health Statistics (US). Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988–94). Appendix B. Hyattsville (MD): NCHS; 1996. Also available from: URL: http://www.cdc.gov/nchs /data/nhanes/nhanes3/nh3gui.pdf[cited 2014 Jul 25].
32. Sanchez DR, Diez Roux AV, Michos ED, Blumenthal RS, Schrei­ner PJ, Burke GL, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol 2011;107:41-6.
33. 2012 Writing Committee Members, Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012;126:875-910.
34. Parekh AK, Galloway JM, Hong Y, Wright JS. Aspirin in the secondary prevention of cardiovascular disease. N Engl J Med 2013;368:204-5.
35. Gindi RM, Ward BW. QuickStats: percentage of adults aged $40 years who ever had a cardiovascular event* and are now taking low-dose aspirin to prevent or control heart disease, by sex and race/ethnicity— National Health Interview Survey, 2012. MMWR Morb Mortal Wkly Rep 2014;63(08):179. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6308a5.htm?s_cid=mm6308a5_e (accessed 25 July 2014).
36. Food and Drug Administration (US). Can an aspirin a day prevent a heart attack? [cited 2014 Jul 25]. Available from: URL: http://www.fda.gov/downloads/forconsumers/consumerupdates/ucm395477.pdf
37. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation 2010;33:1395-402.
38. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014;37 Suppl 1:S14-80.
39. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S-64.
40. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018-24.